Analytical Data
-
基因名
GALNTL1
- Application
-
别名
GALNTL1；GALNTL1；KIAA1130；Polypeptide N-acetylgalactosaminyltransferase 16
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8N428
-
表达区间
1-558aa
-
氨基酸序列
MRKIRANAIAILTVAWILGTFYYLWQDNRAHAASSGGRGAQRAGRRSEQLREDRTIPLIVTGTPSKGFDEKAYLSAKQLKAGEDPYRQHAFNQLESDKLSPDRPIRDTRHYSCPSVSYSSDLPATSVIITFHNEARSTLLRTVKSVLNRTPANLIQEIILVDDFSSDPEDCLLLTRIPKVKCLRNDRREGLIRSRVRGADVAAATVLTFLDSHCEVNTEWLPPMLQRVKEDHTRVVSPIIDVISLDNFAYLAASADLRGGFDWSLHFKWEQIPLEQKMTRTDPTRPIRTPVIAGGIFVIDKSWFNHLGKYDAQMDIWGGENFELSFRVWMCGGSLEIVPCSRVGHVFRKRHPYNFPEGNALTYIRNTKRTAEVWMDEYKQYYYEARPSAIGKAFGSVATRIEQRKKMNCKSFRWYLENVYPELTVPVKEALPGIIKQGVNCLESQGQNTAGDFLLGMGICRGSAKNPQPAQAWLFSDHLIQQQGKCLAATSTLMSSPGSPVILQMCNPREGKQKWRRKGSFIQHSVSGLCLETKPAQLVTSKCQADAQAQQWQLLPHT
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GALNTL1 (Polypeptide N-acetylgalactosaminyltransferase-like 1) is a member of the GALNT gene family, which is responsible for the initiation of mucin-type O-glycosylation, a post-translational modification essential for various biological processes, including cell-cell interactions, cell signaling, and the stability of glycoproteins. Research has shown that GALNTL1 plays a significant role in modulating the glycosylation patterns of proteins, potentially influencing tumor progression and immune responses. The upregulation or downregulation of GALNTL1 has been linked to various cancers, suggesting that it may serve as a crucial biomarker for disease progression or therapeutic targets. Given the complexity of glycosylation processes, the recombinant expression of GALNTL1 has garnered considerable interest in the field of glycoscience and cancer research. Researchers aim to understand the functional implications of GALNTL1 through recombinant technology, enabling the production of biologically active protein for functional assays and structural studies. By elucidating the pathways and mechanisms through which GALNTL1 operates, scientists hope to develop novel strategies for cancer treatment and enhance our understanding of glycosylation's role in human health and disease. This investigation into GALNTL1's function and regulation holds promise for advancing both basic research and clinical applications related to glycosylation and its involvement in key physiological and pathological processes.
